PAIA Biotech has developed a patented platform technology for titer and glycan screening assays in high throughput.

PAIA’s novel technology streamlines bead-based assays by eliminating several assay steps with specially designed microplates, leading to reduced hands-on time and a fully automatable workflow.

We offer assay kits comprising PAIA plates and a combination of functionalised capture beads and a fluorescence marker which is optimised for a given application. Our different antibody quantification assays cover the typical concentrations ranges at the different stages of cell line and bioprocess development. The samples can be measured directly from supernatant without dilution or any sample preparation step.


Ellen Harrington
Technical Sales Specialist

PAIA glycan assays use the same general principle and workflow, but employ markers specific for the glycans present on the antibody or protein of interest.

PAIA assays require a common orbital shakers for incubation and a standard fluorescence readers or microscope for analysis.